Abstract
Adult-onset Still's disease (AoSD), Schnitzler syndrome, and cases of adult-onset autoinflammatory syndromes [10-15% of cases of familial Mediterranean fever (FMF) and tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS)] are characterized by a genetic predisposition, with increased interleukin (IL)-1β and IL-18 production and TNF-α signaling, respectively. As a result, periodic fever and inflammation at barrier tissues (synovial tissues, serous membranes, and the skin) are encountered in such patients. Pathophysiological insights into these diseases have renewed interest in research on IL-1β in rheumatic diseases and have opened new therapeutic avenues. Recently published studies have shown that patients with Schnitzler syndrome, methotrexate-refractory AoSD, and colchicine-refractory FMF or contraindications to colchicines in FMF respond well to treatment with the soluble IL-1 receptor antagonist anakinra. For TRAPS patients, the p75 TNF-α receptor/Fc-IgG1 fusion protein etanercept is the treatment of first choice.
| Translated title of the contribution | Adult-onset Still's disease, Schnitzler syndrome, and autoinflammatory syndromes in adulthood |
|---|---|
| Original language | German |
| Journal | Zeitschrift fur Rheumatologie |
| Volume | 68 |
| Issue number | 9 |
| Pages (from-to) | 740-746 |
| Number of pages | 7 |
| ISSN | 0340-1855 |
| DOIs | |
| Publication status | Published - 11.2009 |
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
